Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Apr:49:102775.
doi: 10.1016/j.msard.2021.102775. Epub 2021 Jan 19.

COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?

Stefano Gelibter  1 , Mario Orrico  1 , Massimo Filippi  2 , Lucia Moiola  1
Affiliations
Comment

COVID-19 with no antibody response in a multiple sclerosis patient treated with cladribine: Implication for vaccination program?

Stefano Gelibter et al. Mult Scler Relat Disord. 2021 Apr.
No abstract available

Keywords: COVID-19; Cladribine; Multiple sclerosis; SARS-CoV-2; Vaccination; vaccine.

PubMed Disclaimer

Conflict of interest statement

S Gelibter and M Orrico have no conflicts of interest to report.

L Moiola has received speaker's honoraria from the following companies: Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, and TEVA.

M Filippi is Editor-in-Chief of the Journal of Neurology; received compensation for consulting services and/or speaking activities from Bayer, Biogen Idec, Merck-Serono, Novartis, Roche, Sanofi Genzyme, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA)

Figures

Fig. 1
Fig. 1.
Timeline of the events described in the present report.
See this image and copyright information in PMC

Comment on

  • COVID-19 in multiple sclerosis patients: susceptibility, severity risk factors and serological response.
    Zabalza A, Cárdenas-Robledo S, Tagliani P, Arrambide G, Otero-Romero S, Carbonell-Mirabent P, Rodriguez-Barranco M, Rodríguez-Acevedo B, Restrepo Vera JL, Resina-Salles M, Midaglia L, Vidal-Jordana A, Río J, Galan I, Castillo J, Cobo-Calvo Á, Comabella M, Nos C, Sastre-Garriga J, Tintore M, Montalban X. Zabalza A, et al. Eur J Neurol. 2021 Oct;28(10):3384-3395. doi: 10.1111/ene.14690. Epub 2021 Jan 9. Eur J Neurol. 2021. PMID: 33340215

References

    1. Moiola L., Barcella V., Benatti S., Capobianco M., Capra R., Cinque P., et al. The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: a Delphi consensus statement. Mult. Scler. 2020;(September) 17135245852095231. - PubMed
    1. Zabalza A., Cárdenas-Robledo S., Tagliani P., Arrambide G., Otero-Romero S., Carbonell-Mirabent P., et al. COVID-19 in MS patients: susceptibility, severity risk factors and serological response. Eur. J. Neurol. 2020;(December) 19;ene.14690. - PubMed
    1. Dersch R., Wehrum T., Fähndrich S., Engelhardt M., Rauer S., Berger B. COVID-19 pneumonia in a multiple sclerosis patient with severe lymphopenia due to recent cladribine treatment. Mult. Scler. 2020;26(10 September):1264–1266. - PubMed
    1. Jack D., Nolting A., Galazka A. Favorable outcomes after COVID-19 infection in multiple sclerosis patients treated with cladribine tablets. Mult. Scler. Relat. Disord. 2020;46(November) - PMC - PubMed
    1. Celius E.G. Normal antibody response after COVID-19 during treatment with cladribine. Mult. Scler. Relat. Disord. 2020;46(November) - PMC - PubMed